FIGURE 3.

A patient with pancreas adenocarcinoma was treated with Ipilimumab (3 mg/kg) every 3 weeks with immune-mediated tumor regression evident after the mid-course 1 evaluation. A–C, The primary tumor (white arrows with the letter “P”) and liver metastases (white arrows) regress after mid-course 1 evaluation in representative tumors. Four new metastases developed between start of treatment and the midcourse evaluation. A new metastasis is shown by the right hepatic vein at midcourse evaluation in (B). D, Tumor markers during the 2 courses of treatment show a decline in all measures after mid course-1 evaluation. E, Change in tumor size relative to size at the presentation of the lesion. Four new hepatic metastases are depicted at mid course-1 evaluation with baseline tumor size measured at 100% at this time point